Gallant News Releases & Company Announcements

Gallant Advances Canine Osteoarthritis IV-Delivered Stem Cell Therapy with Promising Pilot Data and Expanded FDA Conditional Approval Pathway Eligibility

Gallant Reports Positive Pilot Data for Feline Osteoarthritis Stem Cell Therapy; Receives FDA Eligibility for Expanded Conditional Approval Pathway

National Survey: Veterinary Professionals See Stem Cell Therapy as a Powerful New Tool for Inflammatory Diseases in Pets

Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics

FDA Completes Safety for Gallant’s First Ready-to-Use Stem Cell Therapy for Refractory FCGS

Biotech and Veterinary Innovators Dr. Misti Ushio and Doug Drew Join Gallant Board of Directors

Gallant Achieves FDA “Technical Section Complete” for Reasonable Expectation of Effectiveness, Advancing First Ready-to-Use Stem Cell Therapy

Gallant Debuts GallantU: A Comprehensive CE Platform Preparing Veterinary Professionals for the Regenerative Medicine Era

Announcement text on blue background: "Gallant Closes $18 Million Series B"

Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market

Gallant Names Dr. Rebecca Windsor Director of Veterinary Affairs as Company Advances Its Off-the-Shelf Stem Cell Therapy for Cats

Illustration of stem cell therapy study targeting cats and dogs

Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of “Off-the-Shelf” Stem Cell Therapies for Pets

Illustration of a cat at veterinarian exam

Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis

Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)

News Releases

Stay Curious